Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 804730, 6 pages
http://dx.doi.org/10.1100/2012/804730
Clinical Study

A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients

1Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, 20123 Milan, Italy
2Frontier Science & Technology Research Foundation Southern Europe (FSE), 6830 Chiasso, Switzerland
3Data Management Service, Multimedica Group, 20159 Milan, Italy

Received 3 October 2011; Accepted 1 November 2011

Academic Editors: J. Aquavella and I. Lipshitz

Copyright © 2012 Stefano Ranno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To compare the ocular hypotensive effect of tafluprost with prostaglandin analogues (PGAs) in glaucoma patients. Methods. 89 primary open-angle glaucoma patients treated with bimatoprost, latanoprost, or travoprost for at least 3 months complaining for ocular discomfort were switched to tafluprost. IOP was assessed at baseline and 3 months after switching the therapy by daily curve. Primary outcome was to compare the mean daily IOP of tafluprost with PGAs. Results. The mean daily IOP was 16±2.1 and 16.6±2.0?mm Hg at baseline and after switching to tafluprost, respectively (??>0.05). When analysis was carried out between tafluprost and each previous PGAs, the comparison between latanoprost and tafluprost and travoprost and tafluprost did not show any statistically significant difference in mean daily IOP and at each time point. The comparison between bimatoprost and tafluprost showed a statistically significant difference in mean daily IOP (??<0.05) and at each time point (??<0.05). Conclusions. After 3 months of switching tafluprost showed an overall IOP lowering effect similar to others PGAs. When each PGA was compared with tafluprost, bimatoprost showed to provide a statistically significant additional IOP lowering effect.